[go: up one dir, main page]

CY1125116T1 - Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου - Google Patents

Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου

Info

Publication number
CY1125116T1
CY1125116T1 CY20221100282T CY221100282T CY1125116T1 CY 1125116 T1 CY1125116 T1 CY 1125116T1 CY 20221100282 T CY20221100282 T CY 20221100282T CY 221100282 T CY221100282 T CY 221100282T CY 1125116 T1 CY1125116 T1 CY 1125116T1
Authority
CY
Cyprus
Prior art keywords
cancer therapy
btk inhibitor
btk
bruton
pyrimidine
Prior art date
Application number
CY20221100282T
Other languages
English (en)
Inventor
Samantha M. Goodstal
Claude Gimmi-Mckim
Bayard R. Huck
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1125116T1 publication Critical patent/CY1125116T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση προσφέρει μεθόδους θεραπείας του καρκίνου, χρησιμοποιώντας ενώσεις πυριμιδίνης και πυριδίνης, οι οποίες είναι αναστολείς της κινάσης τυροσίνης του Bruton (ΒΤΚ).
CY20221100282T 2015-11-04 2022-04-14 Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου CY1125116T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250575P 2015-11-04 2015-11-04
US201662296143P 2016-02-17 2016-02-17
US201662341189P 2016-05-25 2016-05-25

Publications (1)

Publication Number Publication Date
CY1125116T1 true CY1125116T1 (el) 2024-12-13

Family

ID=57442803

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100282T CY1125116T1 (el) 2015-11-04 2022-04-14 Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου

Country Status (23)

Country Link
US (3) US20170119766A1 (el)
EP (2) EP3371165B1 (el)
JP (4) JP6913100B2 (el)
KR (1) KR20180073599A (el)
CN (1) CN108779095A (el)
AU (3) AU2016349584B9 (el)
BR (1) BR112018007604B1 (el)
CA (1) CA3001735A1 (el)
CY (1) CY1125116T1 (el)
DK (1) DK3371165T3 (el)
ES (1) ES2912059T3 (el)
HU (1) HUE058323T2 (el)
IL (2) IL293093B2 (el)
LT (1) LT3371165T (el)
MX (2) MX2018005461A (el)
NZ (1) NZ741293A (el)
PL (1) PL3371165T3 (el)
RS (1) RS63146B1 (el)
RU (2) RU2022100782A (el)
SG (2) SG11201802927VA (el)
SI (1) SI3371165T1 (el)
TW (2) TWI783915B (el)
WO (1) WO2017079542A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2022100782A (ru) * 2015-11-04 2022-02-03 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
NZ741294A (en) * 2015-11-17 2023-07-28 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
AU2018263921A1 (en) * 2017-05-03 2019-12-05 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
CA3104191A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
WO2022206939A1 (zh) * 2021-04-03 2022-10-06 海南耀臻生物医药科技有限公司 作为fgfr抑制剂的杂环化合物及其应用
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2023247774A1 (en) 2022-06-24 2023-12-28 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649896A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Geformte Seifenprodukte
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
JP4937112B2 (ja) * 2004-03-30 2012-05-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
EP2211615A4 (en) * 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
SG194219A1 (en) * 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US8895750B2 (en) * 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
JP6494633B2 (ja) * 2013-09-22 2019-04-03 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されているアミノピリミジン化合物および使用方法
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
RU2022100782A (ru) * 2015-11-04 2022-02-03 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
NZ741294A (en) * 2015-11-17 2023-07-28 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity

Also Published As

Publication number Publication date
EP3371165A1 (en) 2018-09-12
ES2912059T3 (es) 2022-05-24
CN108779095A (zh) 2018-11-09
SI3371165T1 (sl) 2022-05-31
CA3001735A1 (en) 2017-05-11
PL3371165T3 (pl) 2022-05-02
US20200206224A1 (en) 2020-07-02
IL293093B1 (en) 2024-03-01
AU2021211982B2 (en) 2023-03-02
TW202320784A (zh) 2023-06-01
LT3371165T (lt) 2022-05-10
IL258979A (en) 2018-06-28
AU2016349584B2 (en) 2021-05-13
AU2021211982A1 (en) 2021-08-26
JP2018532805A (ja) 2018-11-08
HUE058323T2 (hu) 2022-07-28
TW201722430A (zh) 2017-07-01
RU2022100782A (ru) 2022-02-03
JP2023105214A (ja) 2023-07-28
MX2018005461A (es) 2018-08-01
TWI783915B (zh) 2022-11-21
BR112018007604A2 (pt) 2018-10-23
JP2025023232A (ja) 2025-02-14
EP3371165B1 (en) 2022-01-26
AU2023203377A1 (en) 2023-06-29
IL258979B (en) 2022-06-01
IL293093B2 (en) 2024-07-01
BR112018007604B1 (pt) 2022-08-16
US20170119766A1 (en) 2017-05-04
RU2018120153A (ru) 2019-12-05
SG11201802927VA (en) 2018-05-30
AU2016349584B9 (en) 2021-06-03
US11491153B2 (en) 2022-11-08
US20210244736A1 (en) 2021-08-12
SG10202005292UA (en) 2020-07-29
IL293093A (en) 2022-07-01
NZ741293A (en) 2023-06-30
RS63146B1 (sr) 2022-05-31
JP6913100B2 (ja) 2021-08-04
TWI858413B (zh) 2024-10-11
WO2017079542A1 (en) 2017-05-11
RU2765154C2 (ru) 2022-01-26
RU2018120153A3 (el) 2020-03-05
EP4014977A1 (en) 2022-06-22
DK3371165T3 (da) 2022-05-02
MX2021015826A (es) 2022-02-03
JP2021165308A (ja) 2021-10-14
KR20180073599A (ko) 2018-07-02
AU2016349584A1 (en) 2018-04-26
JP7295169B2 (ja) 2023-06-20

Similar Documents

Publication Publication Date Title
CY1125116T1 (el) Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου
CY1125289T1 (el) Αναστολεις kras g12c και μεθοδοι χρησης αυτων
CY1125588T1 (el) Θεραπευτικοι συνδυασμοι ενος αναστολεα βτκ και ενος αναστολεα bcl-2
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
CY1124300T1 (el) Μεθοδοι για τη χρηση αγωνιστων fxr
CY1125042T1 (el) Νεα ετεροκυκλικα παραγωγα χρησιμα ως αναστολεις shp2
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
JOP20220087A1 (ar) أمينات ثنائية الحلقة كمثبطات لـ cdk2
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
LT3902803T (lt) Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
CY1123592T1 (el) Αναστολεας κινασης aurora a
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
CY1123892T1 (el) Κρυσταλλικες μορφες του 6-((6,7-διμεθοξυκιναζολιν-4-υλο)οξυ)-ν,2-διμεθυλοβενζοφουρανο-3-καρβοξαμιδιου
EP3543239C0 (en) SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE
DK3601296T3 (da) 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere
JOP20190190A1 (ar) معالجة سرطان